Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.
Open Access
- 1 February 1982
- journal article
- Published by Wiley
- Vol. 13 (2) , 213-217
- https://doi.org/10.1111/j.1365-2125.1982.tb01359.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Active Transport of Sodium and Potassium IonsNew England Journal of Medicine, 1980
- The Measurement of Angiotensin-Converting Enzyme in Subjects Receiving CaptoprilNew England Journal of Medicine, 1980
- Plasma converting enzyme activity (C.E.A.) : An index of plasma levels of captopril?Life Sciences, 1980
- IMMUNE-COMPLEX GLOMERULOPATHY IN PATIENTS TREATED WITH CAPTOPRILThe Lancet, 1980
- IMPROVEMENT OF CHRONIC CONGESTIVE HEART-FAILURE BY ORAL CAPTOPRILThe Lancet, 1979
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978
- Accentuated Vascular and Endocrine Response to Sq 20881 in HypertensionNew England Journal of Medicine, 1977
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977
- A sensitive radioenzymatic assay for norepinephrine in tissues and plasmaLife Sciences, 1975
- RADIOIMMUNOASSAY DETERMINATION OF PLASMA-RENIN ACTIVITYThe Lancet, 1969